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Management of Allergic Rhinitis: 
Focus on lntranasal Agents 
Miriam E. Dushay, Pharm.D. and Cary E. Johnson, Pharm.D. 
The clinical manifestations of allergic rhinitis are the result of an immune-mediated 
process after exposure of a sensitized individual to airborne allergens. The primary 
symptomatology includes nasal congestion, rhinorrhea, nasal and conjunctival 
pruritus, and sneezing. Principles of management include allergen avoidance, 
palliative therapy, immunotherapy, and pharmacotherapy. Oral decongestants 
stimulate a-adrenergic receptors in the nasal cavity, resulting in vasoconstriction 
and decreased edema. Oral antihistamines block histamine, (HI) receptors, and 
may relieve rhinorrhea, sneezing, and nasal and conjunctival pruritus. Topical 
decongestants have a local effect on adrenergic receptors in the nasal mucosa, 
resulting in rapid, marked vasoconstriction. lntranasal corticosteroids inhibit medi- 
ator release from mast cells and basophils, and reduce edema of the nasal muco- 
sa. Dexamethasone sodium phosphate, beclomethasone dipropionate, and fluni- 
solide are currently available for intranasal administration. Cromolyn sodium 
inhibits allergen-induced degranulation and mediator release from sensitized 
cells, and is useful primarily as a prophylactic agent. Several agents, including the 
corticosteroids budesonide and flucortin butylester, the mast cell-stabilizing agent 
nedocromil sodium, the antichololinergic agent ipratropium bromide, and the H, 
receptor antagonist levocabastine are being investigated for intranasal use in the 
management of allergic rhinitis. (Pnarrnacotherapy 1989;9(6):338-350) 
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Rhinitis denotes a condition involving inflamma- 
tion of the nasal mucosa in response to various stim- 
uli, and may be cpnsidered under two headings: 
allergic and nonallergic. Allergic rhinitis is an im- 
munologic process that can produce symptoms 
during specific periods (seasonal) or throughout the 
year (~erennial).'-~ Nonallergic rhinitis collectively 
refers to vasomotor rhinitis and nonallergic rhinitis 
with eosinophilia (NARES). The most commonly ob- 
served types of rhinitis and their distinguishing char- 
acteristics are shown in Table 1 .5-11 Therapeutic 
management of allergic rhinitis is varied, and em- 
phasis currently is on topically active pharmacologic 
agents administered by the intranasal route. 
Allergens are airborne, water-soluble proteins 
present primarily in pollen and mold spore carriers. 
After they are inhaled, these proteins are readily ex- 
tracted from their natural carrier sources, faciliating 
their deposition on nasal epithelial surfaces. In tem- 
perate climates, the most important environmental 
allergens are tree pollens in the spring, grass pol- 
lens in late spring and summer, and ragweed pollen 
in the late summer and fa11.12 The onset and severity 
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Table 1. Types of Allergic and Nonallergic Rhinitis 
Variable Seasonal Perennial NARESa Vasomotor 
Onset 
Cause 
Family history of allergy 
Occurrence of symptoms 
Laboratory tests 
Eosinophilia 
Serum IgE 
Skin tests 
Symptoms 
Sneezing 
Rhinorrhea 
Nasal pruritus 
Nasal polyps 
Congestion 
Lacrimation 
Decongestantsb 
Steroidsb 
Cromolyn” 
ImmunotheraDv 
Therapeutic response to 
Childhood 
Pollens 
Common 
Seasonal 
Present 
Elevated 
Positive 
Frequent 
Profuse, 
watery 
Marked 
Common 
Moderate 
Common 
Fair 
Good 
Good 
Good 
Childhood ~ 
Animal dander, 
house dust, 
mold spores 
Common 
Throughout 
the year 
Present 
Elevated 
Positive 
Frequent 
Profuse, 
watery 
Marked 
Common 
Moderate 
Common 
Fair 
Good 
Good 
Good 
Nonspecific 
Unknown 
Coincidental 
Sporadic; 
throughout 
the year 
Present 
Normal 
Negative 
Sporadic 
Profuse, 
watery 
Moderate 
Occasional 
Minimal 
Common 
Fair 
Good 
None 
None 
Adult 
neNOUS 
system 
disorder 
Coincidental 
Worse in 
changing 
seasons 
Absent 
Normal 
Negative 
Sporadic 
Moderate, 
watery 
Minimal 
Rare 
Marked 
Rare 
Poor 
Poor 
Poor 
None 
aNonallergic rhinitis with eosinophilia. 
bAdrninistered by the intranasal route. 
Adapted from references 5-1 1. 
of symptoms depend on the amount of pollen pres- 
ent in the air, with the highest counts in warm, dry 
climates. In contrast, mold spores may be airborne 
throughout the year, and are commonly found in 
damp, musty places even during the cold winter 
months.12 
Estimates suggest that approximately 20% of the 
population suffers from allergic rhinitis13-15; however, 
the actual number is .difficult to assess due to the 
subjectivity of the symptoms, and to great interpa- 
tient differences in perceived severity and desire for 
medical attention. Peak onset of symptomatic aller- 
gic rhinitis occurs in the adolescent years, with 
equal distribution between the sexes6# 7. l4 Seasonal 
allergic rhinitis (hay fever) is especially common; 
approximately 75% may be attributed to ragweed 
pollen, 40% to grass pollen, and 9% to tree 
Distinguishing features include seasonal appear- 
ance of symptoms, reflecting sensitivity to pollens 
and fungi. By contrast, the perennial condition re- 
sults from sensitivity to airborne household particles 
such as animal dander and house dust mites, which 
are encountered regularly, as well as to seasonal 
allergens. 
Pathophysiology 
The basic nasal functions include filtration, warm- 
ing and humidification of inspired air, modulation of 
air flow, odor and taste detection, contribution to 
vocal resonance, and protection of the lower air- 
ways from inhaled microorganisms and tox- 
i n ~ . ~ ~ * ~ ~ . ~ ~  Many of these functions are possible due 
to the large nasal surface area and tortuous pas- 
sageways in the folds and turbinates of the nose 
(Figure 1). The width of the nasal passages is regu- 
lated largely by sumpathetic mucosal innervation, 
especially of the venous sinusoids. Adrenergic stim- 
ulation, mediated by norepinephrine, results in va- 
soconstriction, reduction in size of the erectile vas- 
cular tissues, and widening of the 13* l6 
Cholinergic stimultion, mediated by acetylcholine, 
stimulates nasal secretions and also produces 
some vasodilatation, vascular engorgement, and 
narrowing of the airways.4* 13* l6 A normal side-to- 
side, alternating pattern, or nasal cycle, occurs in 
which the mucous membrane of one airway swells, 
while that of the other side may shrink. This cyclic 
change generally occurs every 1-4 hours, and is 
mediated by reciprocal sympathetic innervation of 
the erectile tissue, the total nasal resistance remain- 
ing constant.I6 In the case of rhinitis, however, the 
nasal cycle may occur entirely differently, or may not 
occur at a11.16 
Sharp, angular turns inside the nose encourage 
particle deposition from inspired air. The majority of 
particles trapped in the nasal passages are swept 
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up by the mucociliary system and transported away 
from the nasal region at an average rate of 8-9 
rnmlmin~te.~ The sneeze mechanism helps expel 
inhaled particles, using nasal secretions as a vehi- 
cle. Vibrissae present in the anterior nares can effec- 
tively trap nearly all particles larger than 15 p.m, al- 
though filtering capacity falls to 80% for 5-p. particles 
and to 0% for those that are 1-2 ~ m . ~  Impairedciliary 
function may be the result of temperature extremes, 
excessive mucosal dryness, or clinical conditions 
such as cystic fibrosis and asthma in which exces- 
sive secretions overburden ciliary activity. 
The mechanisms of allergic response are com- 
plex. Initial exposures to airborne allergens sti- 
mualte plasma cells in the lymphoid tissue to pro- 
duce allergen-specific IgE antibodies. These 
antibodies bind to the surface of mast cells and ba- 
sophils throughout the body to function as antigen 
(allergen) receptors. After repeat allergen exposure, 
allergenic protein molecules are presented to these 
sensitized cells, especially in the skin, respiratory 
tract, and gastroinestinal tract. Appropriate aller- 
gens bind to cell-bound IgE antibodies, initiating 
release of various proinflammatory mediators, in- 
cluding histamine, kinins, leukotrienes, chemotactic 
factors for eosinophils and neutrophils, platelet-acti- 
vating factor, and several enzymatic activities: tosyl- 
L-arginine methyl ester (TAME) esterase activity is 
most often meas~red.~, 7. 13. These mediators are 
collectively responsible for itching, influx of cells, 
increased vascular permeability and fluid leakage, 
and other tissue effects. 
The response to allergen challenge develops in 
two stages, immediate and late-phase responses. 
The symptomatology initially present after allergen 
inhalation in the laboratory generally subsides with- 
in 1-3 hours, returning the patient to baseline sta- 
 US.^ Chemotactic factors released at the site of the 
initial mast cell degranulation recruit additional me- 
diator cells such as eosinophils, which can partici- 
pate in later inflammatory responses. Reappear- 
ance of nasal symptoms, especially congestion, 
3-1 1 hours (average 4-6 hrs) after the initial episode 
signals the late-phase response, and, while not en- 
tirely explained, involves further release of inflam- 
matory mediators and generation of kin in^.^. 1 4 *  l a  
Late response symptoms are generally most difficult 
to treat.7 
An additonal phenomenon, known as nasal prim- 
ing, determines that decreasing amounts of allergen 
are required to elicit a response with continuing 
exposure (e.g., as a pollen season progres~es).~.~, l 3  
SUPERIOR TURBINATE (CONCHA) 
FRONTAL SINUS 
PHENOIDAL SINUS 
€3 OPENING Nasofrontal duct 
Nasal vestibule 
Eustachian tube 
Soft pa late 
Figure 1. The nose and paranasal sinus. Reprinted with permission from “Medical notes on the common cold,” Bur- 
roughs Wellcome Co., publication no. P199-2, Research Triangle Park, NC, 1972. 
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Several investigators have documented an increase 
in mast cells and basophils in the nasal mucosa 
during the course of a pollen ~ e a s o n . ~ - ~ ’  Nasal prim- 
ing also may explain the increase in responsiveness 
to unrelated allergens often experienced during a 
pollen season, as well as to otherwise nonspecific 
stimuli such as changes in humidity and tempera- 
ture. 
Etiology 
The elements required for the development of al- 
lergic rhinitis include a genetic predisposition for IgE 
response to allergens, appropriate initial exposures, 
and probably, additional determinants of end-organ 
rea~tivity.’~ Although specific sensitivities are not 
genetically transmitted, the predisposition to devel- 
op allergic reactions in general (atopy) appears to 
be inherited. Atopic individuals are likely to develop 
not only allergic rhinitis but also allergic asthma, 
atopic eczema, and IgE-mediated food allergies. In- 
sect venom reactions, including systemic anaphy- 
laxis and adverse drug reactions, are at best mod- 
estly increased in this risk group.I5 
Nasal symptoms similar to those of allergic rhinitis 
may be induced by medications, including reser- 
pine, hydralazine, guanethidine, methyldopa, pra- 
zosin, propranolol and other I3 blockers, certain anti- 
depressants and antipsychotics, estrogens, 
cocaine, and alcohol.7, 1 5 5 2 2 . 2 3  Aspirin and other non- 
steroidal antiinflammatory agents also may produce 
flushing, rhinorrhea, and intense wheezing in sus- 
ceptible  individual^.^, 15.22 Other factors that may 
lead to obstruction of the nasal airways include re- 
spiratory infections, irritant dusts or chemical fumes, 
tobacco smoke, perfumes, strong odors, rising from 
bed in the morning, chilling of the body surface, 
sexual excitement, menstruation, and pregnan~y.~ 
Clinical Findings 
After initial exposure of atopic individuals to sensi- 
tizing allergens, symptoms generally develop within 
2-3 years, often escalate in severity for 2-3 years, 
and then p l a t e a ~ . ~ . ~  The severity of symptoms may 
fluctuate in later life and often diminishes during the 
sixth or seventh decade, although spontaneous, 
complete remissions are uncommon if exposure 
continue~.~. Allergic rhinitis is seldom problematic 
in elderly patients, which may reflect age-related 
changes in the nasal mucosa and decreased im- 
munologic responsiveness in this p~pu la t ion .~*~  
The primary symptoms of allergic rhinitis include 
nasal congestion, paroxysms of repetitive sneezing, 
clear rhinorrhea, lacrimation, and nasal, conjuncti- 
val, and pharyngeal pruritus. These symptoms may 
further involve mucous membranes of the middle 
ears and paranasal sinuses, resulting in ear pop- 
ping, mildly impaired hearing, and a sensation of 
pressure over the cheeks and forehead. Other non- 
specific symptoms include irritability and fatigue (of- 
ten the effect of sleep loss or sedating medications), 
as well as variations in appetite. Chronic mouth 
breathing often begets snoring and excessive dry- 
ness of the mouth and throat. Increasingly severe 
symptoms such as wheezing and loss of olfaction 
may develop; secondary infection is common. Chil- 
dren often demonstrate the so-called allergic salute, 
a maneuver in which the hand deflects the tip of the 
nose upward, presumably to open the passages 
and relieve nasal itching. Repeated over time, this 
results in a transverse crease about 2 cm above the 
nasal tip.24. 25 Young sufferers also develop “allergic 
shiners,” or edematous, dark circles under the eyes 
due to chronic venous c o n g e s t i ~ n . ~ ~ . ~ ~  
Several developmental complications may occur 
in children with allergic rhinitis. Chronic mouth 
breathing may result in recession of the mandible 
and malocclusions, as well as hyperplasia of phar- 
yngeal lymphoid t i s ~ u e . ~ ~ . ~ ~ ,  27 A high, arched palate 
and gross overbite are also c ~ m m o n . ’ ~ , ~ ~  Frequent 
episodes of otitis media may complicate allergic rhi- 
nitis, especially in pediatric patients. Several studies 
support a correlation between histamine- or aller- 
gen-induced nasal changes and eustachian tube 
obstruction; however, the role of nasal allergy in 
otitis media is still a focus of investigation.2e Nasal 
polyps may complicate allergic rhinitis, especially 
when bacterial infection is associated. In turn, pol- 
yps may obstruct normal sinus drainage and pro- 
mote bacterial infection (i.e., sinusitis).’O A definite 
association exists between the occurrence of severe 
or untreated allergic rhinitis and the later develop- 
ment of asthma, although estimates of the risk differ 
among a~th0rities.l~. 29 
Diagnosis 
Since individuals with allergic rhinitis exhibit the 
classic symptoms only on an intermittent basis, di- 
agnosis is often difficult. The most useful information 
is generally obtained from the clinical history, from 
which the chronology and severity of specific com- 
plaints and their response to therapeutic manage- 
ment may be determined. The differential diagnosis 
for allergic rhinitis should include the processes list- 
ed in Table 2.17.23 
Several simple, noninvasive diagnostic tests are 
available, including fiberoptic rhinoscopy of the na- 
sal region. This allows direct inspection of the entire 
nasal mucosa, which appears pale, swollen, and 
bluish gray in patients with rhiniti~.‘~*~O Rhinoscopy 
is also effective for identifying mucosal and anatom- 
ic changes, such as edematous turbinates, nasal 
polyps, and septa1 deviation, and may be especially 
useful in infants and children. Roentgenograms are 
of value primarily to assess nasal mucosal hyper- 
trophy and sinusitis, as well as to detect nasal 
In vivo diagnostic procedures include allergen 
skin testing and nasal provocation testing. The pur- 
pose of skin testing is to identify specific allergen 
polyps.6, l5 
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Table 2. Differential Diagnosis of Rhinitis 
Primary Allergic rhinitis with eosinophilia: seasonal 
or perennial rhinitis 
Nonallergic rhinitis with eosinophilia: vaso- 
motor or atrophic rhinitis 
Anatomic deviations: nasal septa1 devi- 
ation, nasal polyps, primary nasal mas- 
tocytosis, adenoidal hypertrophy, 
choanal atresia, impacted foreign body, 
cerebrospinal fluid leak 
Infectious: bacterial, viral, or fungal infec- 
tion 
Endocrine disorder: hypothyroidism, 
pregnancy 
Congenital syphilis, Crohn’s disease, vas- 
culitic disease. cvstic fibrosis 
Secondary 
Other 
Adapted from references 17, 23. 
sensitivities by intradermal injection of dilute aller- 
gen extracts. Various types are used, including the 
epicutaneous, or prick test, for screening large num- 
bers of potential allergens. This may be followed by 
the more sensitive intradermal test, using allergens 
that cause a positive response to epicutaneous in- 
jection. A positive skin test reaction may be noted 
within 10-30 minutes, and is manifested by a large 
wheal and flare at the injection site.3’ Skin testing 
may be of predictive value for future development of 
symptomatic disease, and is routinely performed in 
all patients prior to the initiation of irnmun~therapy.~’ 
Advantages are the rapidity of response and rela- 
tively low patient discomfort: disadvantages include 
a 5 3 5 %  false positive rate, a false negative or re- 
duced response caused by a number of drugs, and 
a risk of anaphyla~is.~’ 
The nasal provocation or challenge test involves 
controlled introduction of histamine, methacholine, 
or specific allergens by atomizer into the nasal cav- 
ity. In sensitive individuals, this challenge produces 
a vigorous reaction marked by sneezing, nasal con- 
gestion, and rh in~r rhea.~~ This form of testing is not 
pleasant for the patient, and may cause significant 
discomfort in the nasopharynx. It may be indicated 
when the results of skin testing or in vitro testing 
conflict with clinical assessment, or to monitor the 
onset and duration of immunotherapy. 
In vitro testing methods include examination of a 
nasal smear and measurement of serum IgE con- 
centrations. Staining of the nasal smear highlights 
eosinophils and other cell types present. Evaluation 
of serum IgE may be accomplished by the radioller- 
gosorbent (RAST) test, Phadiatop method, or en- 
zyme-linked immunosorbent assay (ELISA); these 
methods can help ascertain both the concentration 
and the allergen specificity of IgE present in the 
~ e r u m . ~ * < ~ ~  In vitro test results correlate well with 
those obtained by other diagnostic methods, and 
may be used when skin testing is not feasible, such 
as in patients with eczema. 
Treatment 
General Principles 
The primary goal in managing allergic rhinitis is to 
achieve maximum symptomatic relief with minimum 
adverse effects. The principles of management in- 
clude allergen avoidance, pharmacotherapy, and 
immunotherapy. 
Minimizing patient exposure to offending aller- 
gens is not always easily accomplished, especially 
in the case of airborne agents from natural sources. 
Patients should note that pollen prevalence is high- 
est in warm, sunny, dry weather and lower during 
damp or cold periods. Strategies for avoiding out- 
door allergens center on keeping windows closed 
(feasible through use of air-conditioning units with 
appropriate filters) and precautions during lawn and 
garden work. For brief, predictable outdoor expo- 
sures, felted fiber masks (e.g., 3M Pollen Mask) may 
give substantial protection. Avoidance of indoor al- 
lergens is facilitated by careful house cleaning, 
keeping dogs and cats outside as much as possi- 
ble, and use of zippered plastic encasings over mat- 
tresses, box springs, and pillows. Obvious dust col- 
lectors such as thick carpeting, heavy draperies, 
and uncleaned venetian blinds should be eliminat- 
ed, especially in the bedroom. Electrostatic precipi- 
tators are often recommended, but remain to be 
proved clinically 
Palliative therapy may include air humidification 
and nasal irrigation with sodium chloride solutions, 
especially in extremely dry climates or as an adjunct 
in treating secondary infection. Nasal irrigations 
soothe the inflamed mucosa, help clear tenacious 
mucus, and improve ~ l f a c t i o n . ~ ~ - ~ ~  Two approaches 
are available for nasal irrigation: commercial buf- 
fered sodium chloride preparations such as Nasal, 
Saline X, Ayr, and Ocean, which are sprayed into 
each nostril several times daily as needed, and iso- 
tonic sodium chloride solutions made from one- 
fourth teaspoon of. iodine-free salt in 7 oz warm wa- 
ter, instilled with a bulb syringe or Water-Pik as 
needed.37, 38 
Despite its long history of proved value in the 
management of nasal allergy, immunotherapy is re- 
served primarily for severe cases of rhinitis and pa- 
tients refractory to standard pharma~otherapy.’~ lm- 
munotherapy seeks to decrease the allergic 
response through a series of subcutaneous injec- 
tions providing increasing doses of specific allergen 
extracts. The injections result in production of IgG- 
blocking antibodies to the administered allergens, 
which reduce mast cell and basophil degranulation 
and diminish the inflammatory response after aller- 
gen exposure. Both magnitude and duration of the 
therapeutic response are directly related to the cu- 
mulative dose of allergen admini~tered.’~ Immun- 
otherapy can provide substantial, long-lasting 
symptomatic relief to patients with allergic rhinitis; 
however, it seldom provides a permanent cure, and 
includes a low but definite risk of anaphylactic reac- 
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Table 3. Nasal Decongestant Products 
Adult Dose Age 6-1 2 yrs Age 2-6 yrs 
Strengths (dropdsprays (drops/sprays (drops/sprays 
producta Available per nostril) per nostril) per nostril) 
- 
Catecholamines 
Epinephrine HCI 
Ephedrine SO, 
Phenylephrine HCI 
lmidazole derivatives 
Naphazoline HCI 
Oxymetazoline HCI 
Tetrahydrozoline 
Xylometazoline HCI 
Propyl hexedrine 
Other 
Desoxyephedrine 
0.1% 
0.5% 
1 .O% 
0.125% 
0.25% 
0.5% 
1 .O% 
0.025% 
0.05% 
0.025% 
0.05% 
0.05% 
0.1% 
0.05% 
0.1 % 
250-mg 
nasal 
inhaler 
50 mg 
nasal 
inhaler 
2-3 as needed 
2-3 every 4 hrs 
2-3 every 4 hrs 
NRC 
1-2 every 3-4 hrs 
1-2 every 3-4 hrs 
1-2 every 3-4 hrs 
NR 
NR 
NR 
NR 
1-2 every 4-6 hrs 
2-3 every 12 hrs 
2-4 every 4-6 hrs 
2-3 every 8-10 hrs 
2 inhalations every 2 or 
more hrs 
2 inhalations every 2 or 
more hrs 
2-3 as needed NEb 
1-2 every 4 hrs NE 
1-2 every 4 hrs NE 
1-2 every 3-4 hrs NR 
1-2 every 3-4 hrs NR 
NR NR 
NR 2-3 every 4 hrs 
1-2 every 4-6 hrs 
2-3 every 12 hrs 
2-4 every 4-6 hrs 
2-3 every 8-10 hrs 
NR 
NR 
NR 
NR 
NE 
NE 
2-3 every 12 hrs 
NR 
2-3 every 3-6 hrs 
NR 
2-3 every 8-1 0 hrs 
NR 
2 inhalations every 2 or NE 
more hrs 
2 inhalations every 2 or NE 
more hrs 
aProduct should be discontinued after 3-5 days to prevent rebound congestion. 
bNE = Safety and efficacy data have not been established for use in children less than 6 years of age. 
CNR = Use of this concentration is generally not recommended by the manufacturers for this age group. 
Adapted from references 37-42. 
tions at any time during the treatment.I5 The couse 
of injections must also be repeated before each al- 
lergy season, or continued on a maintenance 
schedule throughout the year. 
Oral Decongestants and Antihistamines 
Initial pharmacotherapy of rhinitis often includes 
oral decongestants and emphasizes the use of anti- 
histamines. Oral decongestants are sympathomi- 
metic amines that stimulate a-adrenergic receptors 
in the nasal mucosa, resulting in vasoconstriction 
and decreased tissue edema.37-39 Systemic adverse 
effects include tachycardia, palpitations, nervous- 
ness, tremor, insomnia, and hypertension in predis- 
posed individuals. 
Special risks exist in patients with closed-angle 
glaucoma, bladder outlet obstruction, and impaired 
gastrointestinal m ~ t i l i t y . ~ ~ - ~ ~  Oral decongestants 
commonly used include ephedrine, pseudoephe- 
drine, phenylephrine, and phenylpropanolamine. 
These agents minimally suppress rhinorrhea, 
sneezing, and nasal pruritus, and are therefore best 
used concurrently with oral antihistamines. Antihis- 
tamines inhibit the binding of histamine to H, recep- 
t o r ~ . ~ ~ ~ ~ ~  Adverse effects include drowsiness, dizzi- 
ness, epigastric distress, and anticholinergic effects 
such as dry mouth, urinary retention, and constipa- 
tion . 37-39 Popular oral antihistamines for allergic rhi- 
nitis include chlorpheniramine, brompheniramine, 
and triprolidine. Newer agents such as terfendine 
and astemizole tend to cause significantly less se- 
d a t i ~ n . ~ ~ - ~ ~  Further discussion of the oral deconges- 
tants and antihistamines used in allergic rhinitis is 
beyond the scope of this article; a thorough review 
of these agents may be found el~ewhere.~’-~~ 
Topical Decongestants 
Topical decongestants are often used as initial 
intranasal therapy for allergic rhinitis (Table 3).37-42 
The catecholamine and imidazole derivatives act 
preferentially on a-adrenergic receptors in the mu- 
cosa, causing marked vasoconstriction and de- 
creased edema.37-40 Propylhexedrine and desoxy- 
ephedrine indirectly stimulate a-adrenergic 
receptors by a mechanism similar to that of amphet- 
amine.41-42 Improvements in nasal ventilation and 
control of rhinorrhea generally occur within 5-1 0 
minutes of topical decongestant application. The ca- 
techolamine derivatives provide a rapid effect of 
short (average 4 hrs) duration, while the imidazole 
products offer a rapid effect with a substantially 
longer (9-1 2 hrs) duration. Propylhexedrine and de- 
soxyephedrine have a very short (1 -2 hrs) duration 
and are therefore less desirable. 
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Adverse reactions to these agents include sneez- 
ing, nasal burning, mucosal dryness, and, rarely, 
bleeding.38,39 Patients may experience nasal irrita- 
tion due to product pH or the presence of additives 
such as antioxidants and preservatives. Systemic 
side effects after intranasal administration are gen- 
erally rare, since the amount of drug absorbed is 
relatively small and metabolism is rapid.38 
Prolonged therapy (~3-5 days) or excessive ap- 
plication of the topical decongestants can result in 
mucosal ischemia, edema, and rebound conges- 
tion, collectively known as rhinitis medicamen- 
tosa.10,37*43 This phenomenon has not been associ- 
ated with oral  decongestant^.^^ It is treated by 
immediate discontinuation of the topical deconges- 
tant. Isotonic sodium chloride preparations may of- 
fer symptomatic relief, and some patients may re- 
quire a brief course of intranasal corticosteroid 
therapy.37 
Topical decongestants are useful for short-term, 
symptomatic relief and control of rhinorrhea, but do 
not effectively inhibit the nasal response to aller- 
gens. They may be used on initiation of intranasal 
corticosteroid or cromolyn sodium therapy to im- 
prove nasal penetration of these agents. The longer- 
acting imidazole products require less frequent dos- 
ing and are therefore more convenient; they are also 
less likely to cause rebound congestion when ap- 
plied in an appropriate dosage for a short course of 
therapy.40 Patients should be cautioned not to use 
topical decongestants, especially the highly con- 
centrated, long-acting preparations, for more than 
3-5 consecutive days, and should be advised 
against exceeding the recommended dosage.37* 40
Several topical decongestant products can be used 
in children over 2 years of age, provided the appro- 
priate concentration is selected and administered 
according to manufacturers’ recommendations (see 
Table 3) ,37-42 
Corticosteroids 
The development of potent corticosteroids for in- 
tranasal administration has been a major advance in 
the management of allergic rhinitis. The therapeutic 
effect produced by these agents is not completely 
understood, but is thought to involve inhibition of 
allergen-induced mediator release from mast cells 
and basophils, inhibition of mast cell and basophil 
accumulation on the nasal mucosal surface, reduc- 
tion in the number of eosinophils present in nasal 
secretions, inhibition of leukocyte chemotaxis, inhi- 
bition of prostaglandin and leukotriene generation, 
and direct ~ a ~ ~ ~ ~ n ~ t r i ~ t i o n . ~ ~ ~  38* 44. 45 ln ranasal corti- 
costeroid therapy has been shown to inhibit both the 
early and late inflammatory responses after allergen 
challenge.44. 46 
Dexamethasone sodium phosphate (Decadron 
Turbinaire) was introduced in 1968 as the first corti- 
costeroid with an intranasal dosage form. While it 
was effective in relieving the symptoms of allergic 
rh in i t i~ ,~~.  47 side effects resulting from significant 
systemic absorption of active drug with suppression 
of the hypothalmic-pituitary-adrenal (HPA) axis sig- 
nificantly limited its use.48-51 Fortunately, several 
topically active hydrocortisone derivatives with 
maximized antiinflammatory potency and highly li- 
pophilic structures have subsequently been synthe- 
sized; these include beclomethasone dipropionate, 
flunisolide, and the investigational agents budeson- 
ide and flucortin b~ ty les te r .~ * -~~  
The antiinflammatory activities of beclometha- 
sone dipropionate (BDP) and flunisolide are, re- 
spectively, 5000 and 3000 times greater than that of 
hydrocorti~one.~~, 44 Both agents are indicated for 
treatment of seasonal and perennial allergic rhinitis 
and normal nonallergic rhinitis with eosinophilia, 
and for the prevention of recurrent nasal pol- 
y p ~ . ~ ~ ,  54-57 They also effectively reduce inflammation 
and stabilize the nasal mucosa in rhinitis medica- 
m e n t ~ s a . ~ ~ ,  38- 47 
Both BDP and flunisolide are rapidly absorbed 
from the nasal mucosa and the gastrointestinal tract 
after intranasal administration and partial swallow- 
ing of the dose. Drug that is swallowed undergoes a 
rapid first-pass hepatic metabolism to relatively in- 
active metabilites. Drug absorbed from the nasal 
mucosa initially avoids the first-pass metabolism, 
but is ultimately metabolized in the liver. These 
agents are highly bound to plasma proteins. The 
serum elimination half-life is approximately 15 hours 
for BDP38*44 and 1-2 hours for f l~n iso l ide~~;  serum 
levels, however, do not correlate with the local in- 
tranasal effect. 
Adverse effects with intranasal BDP and fluniso- 
lide include nasal burning, irritation, sneezing, con- 
gestion, minor headache, and infrequent nose- 
bleeds. Other adverse effects may include transient 
lightheadedness and reversible loss of taste and 
smell.58 Spraying the aerosol toward the nasal sep- 
tum rather than the turbinates may result in hemor- 
rhagic crusting of the septum; rare cases of nasal 
mucosal ulceration have been Septa1 
perforations due to unknown causes have been re- 
ported with these drugs,60-62 the effect being pre- 
ceded in some instances by severe nasal crusting 
and bleeding. No significant metaplastic or atrophic 
changes in the nasal mucosa have been seen after 
up to 5 years of use for either agent.44* 47- 58,63-66 Nasal 
candidiasis is rare.58-64,65,67 Both BDP and fluniso- 
lide produce a dose-dependent decrease in nasal 
ciliary beating frequency in vitro; further investiga- 
tion is needed to evaluate their potential effects on 
mucociliary clearance in V ~ V O . ~ ~ .  68- 69 Unlike dexa- 
methasone, neither drug produces overt suppres- 
sion of the HPA axis when administered in recom- 
mended dosages for prolonged courses.58. 65- 66. 71- 71 
Recommended dosages of BDP and flunisolide 
are shown in Table 4.389 54-58. 72-75 Clinicians generally 
initiate therapy at the higher dosages in order to 
provide early maximum suppression of symptoms. 
Dosages should be adjusted based on clinical re- 
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Table 4. Products Currently Available for lntranasal Therapy of Rhinitis 
- 
Generic Name Trade Name Recommended Dosage Available From 
Dexamethasone Decadron Adults: 2 sprayshostril 2-3 times daily 1 OO-kg/spray; freon-propelled 
phosphate 
Turbinaire 
Children 6-12 yrsa: 1-2 sprays/nostril 2 times 
daily 
dipropionate Vancenase 2-4 times daily, or 2 sprays/nostril 2 times 
daily 
Children 6-1 2 yrsa: 1 spraylnostril3 times daily 
Adults and children >6yrsa: 1-2 sprays/nostril 
Children 6-1 4 yrsa: 1 spraylnostril3 times dai- 
Beclomethasone Beconase, Adult and children > 12 yrs: 1 spray/nostril 42-~g/spray; freon-propelled 
Beconase AQ, 
Vancenase AQ 2 times daily 
42-p,g/spray; metered pump 
Flunisolide Nasalide Adults: 2 sprays/nostril 2-3 times daily 25-p.g/spray; metered pump 
ly, or 2 sprays/nostril 2 times daily 
Cromolyn sodium Nasalcrom Adults and children >6 yrsa: 1 spray/nostril 4% nasal solution: 5.2 mglspray 
3-6 times daily 
aSafety and efficacy data have not been established for use in children less than 6 years of age. 
Adapted from references 38, 51, 54-58, 72-76. 
sponse and patient tolerance, and should be re- 
duced to the lowest maintenance level possible 
once symptoms have been controlled. Use of higher 
than recommended dosages has not provided addi- 
tional benefit, and it increases the risk of systemic 
adverse  effect^.^^-^^ Relief of symptoms usually be- 
gins within 2-3 days of initiating therapy; maximum 
response may require 2-3 weeks in some 
patients.37- 65 
It is essential that patients understand the rate of 
response to be expected from intranasal steroids 
and that these products require regular use for maxi- 
mum benefit. Therapy should be continued 
throughout the expected season for hay fever, and 
may be required on a long-term basis for perennial 
allergic rhinitis. Patients who are receiving inhalation 
BDP for asthma and who also require intranasal 
BDP for management of rhinitis may receive total 
daily doses that exceed generally recommended 
doses; prescribers should be aware of the potential 
for increased systemic steroid side effects. 
The major difference among the intranasal corti- 
costeroid preparations is the delivery system. Be- 
conase and Vancenase are generically equivalent, 
each delivering 42 pg of BDP per Me- 
tered-dose spray preparations of these agents use 
freon as an aerosol propellant, which promotes ex- 
cessive drying, crusting, and occasional minor 
bleeding of the mucosa.37.54*55,57 The force of the 
aerosal spray is also not well tolerated by many pa- 
t i e n t ~ . ~ ~ ,  77-79 Nasalide is a finger-operated mechani- 
cal nasal pump spray that delivers an aqueous sus- 
pension of drug.56- 57. 8o Propylene and polyethylene 
glycol are included in the formulation to facilitate 
spreading of the liquid over the nasal mucosa.47.56-80 
The pump spray system is generally better tolerat- 
ed; however, the acidic pH and high (20%) propy- 
lene glycol content of Nasalide produces consider- 
able stinging and burning in many A 
recent report from Canada describes improved pa- 
tient acceptability with an investigational formulation 
of flunisolide (Rhinalar) containing less (5%) propy- 
lene glycol.8o 
Aqueous formulations of BDP are now available 
(Beconase AQ, Vancenase AQ) in pump spray deliv- 
ery systems similar to Nasalide but with a more ac- 
ceptable pH. The aqueous products have been 
shown to be as effective as the pressurized sprays in 
alleviating the symptoms of rhinitis, are better toler- 
ated, and are generally preferred over the pressur- 
ized spray p r ~ d u c t s . ~ ~ - ~ ~  
The recommended dosage of Beconase AQ and 
Vancenase AQ for adults and children above 6 years 
of age is 1-2 sprays in each nostril twice daily.74a75 
While not endorsed by manufacturers, children un- 
der 6 years of age with allergic rhinitis have been 
successfully treated with BDP 1 spray per nostril 3 
times daily,81 or flunisolide 2 sprays per nostril 2 
times daily.@ Although either formulation of BDP 
would be reasonable for use in the pediatric popula- 
tion, an aqueous preparation may be better tolerat- 
ed. All patients receiving intranasal corticosteroids 
should be carefully monitored both for therapeutic 
response and adverse effects, including clinical 
changes in the nasal mucosa and bleeding. 
Budesonide is a synthetic, nonhalogenated corti- 
costeroid with relative antiinflammatory activity com- 
parable to that of BDP and flunisolide. It is currently 
available in Europe (Rhinocort) as a metered-dose 
nasal inhaler for allergic r h i n i t i ~ . ~ ~  Budesonide has 
been shown to be effective, compared to placebo, in 
treating seasonal and perennial nasal allergy, vaso- 
motor rhinitis, and nasal p o l y p o ~ i s . ~ ~ - ~ ~  It appears to 
be most effective in reducing nasal congestion, rhin- 
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Table 5. Comparative Efficacies of the lntranasal Agents 
Comparison Daily Dose (p.g/) Results 
BDP vs FLU 4001200 BDP = FLUg5 
BDP vs FLU 4001200 BDP = FLUg6 
BDP vs FLU 4001200 BDP = FLUg7 
BDP vs FLU 4001200 BDP = FLUg8 
BDP vs FLU 4001200 BDP = FLUg9 
BDP vs BUD 4001400 BDP = BUD'" 
BDP vs BUD 4001400 BUD > BDP'O' 
BDP vs BUD 400I40Oa BUD> BDP'02 
FLU vs BUD 2001400 FLU = BUD'03 
BDP vs CRO 400131.2 mgb BDP>CR01°4 
BDP vs  CRO 400110 mg BDP>CR01°5 
FLU vs CRO 200131.2 mgb FLU>CRO'O~ 
BDP vs FLU or CRO 
BUD vs CRO 400/26 mgb B U D > C R O ' ~ ~  
3361200141.6 mg BDP = FLU > ~ ~ 0 1 0 7  
FLU vs LEV 20010.4 mg FLU = LEV' O9 
aBoth regimens were administered on an as-needed basis. 
bCrornolyn used was a 2% solution; current formulation contains 4% crornolyn. 
BDP = beclomethasone dipropionate; FLU = flunisolide; CRO = crornolyn sodium; BUD = budesonide; LEV = 
levocabastine sodium 
orrhea, and sneezing. The drug is rapidly and com- 
pletely absorbed from the nasal mucosa. Absorbed 
drug is rapidly inactivated by liver enzymes, with a 
hepatic extraction ratio of 90% and a serum elimina- 
tion half-life of 2 hours.88 Adverse effects include 
nasal stinging, minor sore throat, dry nose, and 
slight nasal bleeding.83s87 One case of contact ecze- 
ma involving the nasal mucosa and surrounding tis- 
sues was reported after the use of Rh ino~or t .~~  Bu- 
desonide produces few systemic adverse effects 
and has not caused demonstrable adrenal suppres- 
sion.84*86*88 Unlike BDP and flunisolide, it has mini- 
mal effect on the frequency of nasal ciliary beats.g0 
No morphologic changes in the nasal mucosa have 
been observed after its use for up to 1 year, and no 
cases of intranasal candidiasis have been report- 
ed.84-87 Budesonide is administered by freon-pro- 
pelled, metered-dose spray, delivering approxi- 
mately 50 k g  per actuation. The recommended 
dosage is 2 sprays twice daily into each nostril (400 
kg/day), which may be reduced to 1 spray per nos- 
tril twice daily after symptomatic r e s p ~ n s e . ~ ~ , ~ ~  
Flucortin butylester is also a synthetic, lipophilic, 
hydrocortisone derivative with potent topical antiin- 
flammatory activity. It is available in West Germany 
as a powder for nasal insufflation, with lactose add- 
ed as an excipient to facilitate disper~ion.~' A special 
hand-activated device (Rhinolater) delivers 0.5 mg 
of flucortin per actuation into a plastic Venturi tube 
from which the drug is intranasally inhaled without 
the assistance of an aerosal pr~pellant.~' Flucortin 
appears effective in treating seasonal and perennial 
allergic rhinitis, as well as nonallergic rhinitis, at daily 
dosages of 2-8 mg given in 2-4 equally divided 
intranasal d o s e ~ . ~ l - ~ ~  Symptomatic relief was report- 
ed to appear early and progress during the course 
of therapy.93 After intranasal administration, flucortin 
is metabolized by nonspecific tissue esterases to 
metabolites with little or no glucocorticoid activity, 
thereby producing little risk of systemic corticoster- 
oid e f f e ~ t s . ~ ~ . ~ ~  Reported adverse effects include irri- 
tation of the mucous membranes, postnasal drip, 
sneezing, nasal crusting, headache, and nau- 
sea.92*93 No systemic adverse effects have been re- 
ported, and HPA axis suppression has not been 
observed at dosages 20-80 times the normal daily 
dose.93 
Studies have compared the relative efficacies of 
intranasal corticosteroids for rhinitis (Table 5).95-103 
As BDP and flunisolide have shown comparable 
therapeutic e f f i c a ~ y , ~ ~ - ~ ~  the decision to use either 
agent is generally based on prescriber and patient 
preference. Budesonide appears equally effective 
as, and in some cases more effective than, BDP and 
flunisolide in the treatment of r h i n i t i ~ , ' ~ ~ - ' ~ ~  and may
soon offer a therapeutic alternative to currently avail- 
able agents. 
Mast Cell Stabilizers 
Cromolyn sodium is a derivative of the natural 
product khellin. Its mechanism of action in allergic 
rhinitis is to stablize mast cell membranes, appar- 
ently by inhibiting calcium transmembrane flux and 
thereby preventing antigen-induced degranulation. 
It is more effective in stabilizing mast cells than ba- 
sophils, and therefore may not completely relieve 
~ y m p t o m s . ~ ~ a ~ ~ *  ' l o  Cromolyn does not inhibit the 
binding of IgE to mast cells or interfere with the 
interaction between cell-bound IgE and antigen.38 
Cromolyn can be effective in reducing sneezing, 
rhinorrhea, and nasal pruritus, is minimally useful in 
nonallergic types of rhinitis, and has little effect on 
mucociliary t ran~pott . '~~ 38* It often prevents the 
symptoms of both seasonal and perennial allergic 
rhinitis, and diligent prophylaxis can significantly re- 
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duce both immediate and late symptoms after aller- 
gen exposure. Tachyphylaxis due to the intranasal 
effects of cromolyn has not been reported; it may be 
more difficult to achieve maximum therapeutic re- 
sponse once symptoms have developed.38, l o  
Less than 7% of an intranasal dose of cromolyn is 
absorbed systemically.’ l o  Absorbed drug is rapidly 
excreted unchanged in urine and bile, with a serum 
elimination half-life of 1-2 hours. The remainder of 
the dose is swallowed, with minimal gastrointestinal 
absorption, and excretion primarily in the fe- 
C ~ S . ~ ~ . ” ~ . ’ ~ ’  Adverse effects occur in less than 10% 
of patients, and most commonly include sneezing, 
nasal stinging, nasal burning, transient headache, 
and an unpleasant a f t e r t a ~ t e . ~ ~ . ~ ~ ,  l l 1  Patients 
may also experience mucosal irritation due to the 
preservatives benzalkonium chloride and ethyl- 
enediaminetetraacetic acid. Cromolyn is effective 
and well tolerated in both adults and older children: 
however, safety during pregnancy and in children 
under 6 years of age has not been positively estab- 
l i ~ h e d . ~ ~ .  110 
Cromolyn is currently available as a 4% nasal so- 
lution (Nasalcrom) in a pump spray delivery system. 
The recommended initial dosage for adults and chil- 
dren 6 years of age and older is l spray (5.2 mg) in 
each nostril 3-4 times daily, increasing as needed 
up to 6 times daily.72.110.111 Although not recom- 
mended by the manufacturer, cromolyn has been 
administered to children under 6 years of age as 1 
inhalation per nostril 3-4 times daily, with careful 
monitoring for therapeutic re~ponse.”~ Nasal pas- 
sages should be cleared to the best extent possible 
prior to administration. For management of season- 
al rhinitis, treatment should begin 2-4 weeks prior to 
contact with offending allergens, and should contin- 
ue throughout the period of exposure. Due to the 
delayed onset of effect, concurrent decongestant or 
antihistamine therapy may be indicated. It is essen- 
tial for patients to understand the rate and extent of 
repsonse to be expected from intranasal cromolyn, 
and that, since the product is prophylactic, it must 
be used on a regular basis for maximum benefit. 
Several studies have compared the therapeutic 
efficacy of cromolyn nasal solution to that of the 
intranasal corticosteroids in allergic rhinitis (see Ta- 
ble 5).104-108 Results from open, parallel studies of 
3-8 weeks’ duration showed BDP and flunisolide to 
be more effective than cromolyn in controlling symp- 
toms.106~ lo7 A double-blind, crossover study in pa- 
tients with perennial allergic rhinitis also found BDP 
superior to cromolyn after 4 weeks of therapy.lo4 
Finally, budesonide demonstrated a superior thera- 
peutic effect to cromolyn in controlling nasal symp- 
toms after 3 weeks of therapy in patients with sea- 
sonal rhinitis.lo8 
Similar to cromolyn sodium, nedocromil sodium is 
an investigational mast cell-stabilizing agent.’ l 4  Sev- 
eral placebo-controlled studies have demonstrated 
the efficacy of nedocromil sodium 1% nasal spray in 
preventing symptoms of allergic rhinitis.l15-l17 The 
recommended dosage is 1 spray (1.3 mg) in each 
nostril 2 times daily.115-117 Adverse effects include 
slight nasal irritation and stinging, sneezing, and un- 
pleasant taste.l15-l17 Like cromolyn, nedocromil is 
recommended primarily for prophylactic use, and 
therapy should be initiated 2-4 weeks prior to signifi- 
cant seasonal allergen exposure. 
Miscellaneous Agents 
lpratropium bromide (Atrovent) is a topically ac- 
tive derivative of atropine available in the United 
States as a metered-dose inhaler for oral administra- 
tion in the management of chronic bronchitis and 
reactive airways disease. The drug is also available 
in Europe as a nasal spray for topical administration 
in the management of nasal hypersecretion.6 By 
blocking acetylcholine-mediated responses, ipra- 
tropium decreases tissue concentrations of cyclic 
guanosine monophosphate, resulting in reduced 
volume of nasal secretions and some minor degree 
of vasoconstriction.’l8. 119 Administered intranasally 
from the inhaler both with and without a special na- 
sal adaptor, ipratropium has been shown rapidly 
and effectively to reduce mucosal hypersecretion 
provoked by methacholine challenge,11g and effec- 
tively to decrease rhinorrhea in patients with peren- 
nial allergic,12o, 121  aso or not or,^^^-'^^ and viral rhini- 
It has no effect on basal mucus secretion, 
sneezing, or nasal congestion, and it does not af- 
fect the nasal mucociliary transport sys- 
l18. l19. 121. 122. 126 It reduces excessive secre- 
tions for 8 hours or more after intranasal administra- 
tion 118.121 
Ipratropium’s quaternary ammonium structure re- 
sults in minimal absorption after topical administra- 
tion.12’ The recommended dosage is 2 sprays (20 
pglspray) into each nostril 4 times daily.118.121 Ad- 
verse effects include nasal irritation, nasal stuffi- 
ness, mucosal dryness, headache, and dry or sore 
throat.118, 120. 122. 124 Extremely high dosages (400 pg 
4 times daily) have been associated with systemic 
anticholinergic effects such as dizziness, blurred vi- 
sion, nausea, abdominal pain, constipation, and uri- 
nary retention.121 No significant adverse effects have 
been reported with long-term therapy.118s123 Al- 
though neither the nasal spray nor the nasal adaptor 
for the oral metered-dose inhaler is currently avail- 
able in the United States, ipratropium has the poten- 
tial to be a useful agent for managing conditions that 
produce nasal hypersecretion. An adaptor for the 
oral metered-dose inhaler can be made by cutting 
the tip off a rubber baby bottle nipple and placing it 
over the mouthpiece; the spray can then be directed 
into the nasal passages. 
Levocabastine, a selective H, receptor antagonist, 
is currently under investigation for use in allergic 
rhinitis based on prior successful topical use in aller- 
gic conjunctivitis and allergic r h i n ~ ~ ~ n j ~ n ~ t i v i t i ~ . ~ ~ ~  
Topical use of antihistamines may avoid the seda- 
tion observed with systemic therapy and provide 
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higher drug concentrations at the primary site of 
action. Compared to placebo, 2 metered sprays 
(0.05 mg/spray) of levocabastine per nostril have 
been shown significantly to reduce rhinorrhea and 
sneezing, but not nasal obstruction, in nasal aller- 
gen provocation tests.120, Iz9 Levocabastine, admin- 
istered as 2 sprays per nostril 4 times daily for 3 
months, effectively reduced rhinorrhea and sneez- 
ing in patients with both perennial allergic and non- 
allergic rh in i t i ~ . ’~~  In an open, parallel, comparative 
study, no significant difference in response was ob- 
served between maintenance regimens of intrana- 
sal flunisolide and levocabastine after 4 weeks of 
therapy in patients with seasonal rhinitis.log No ad- 
verse effects have been reported.lo9- 120-130 While le- 
vocabastine promises to be a useful agent,1na-130 its
therapeutic role in allergic rhinitis remains to be de- 
termined. 
Summary 
Allergic rhinitis is a very common disease, with the 
potential to cause great discomfort and diminished 
quality of life. Allergen avoidance, the most effective 
approach in preventing rhinitis, is often difficult or 
unfeasible to accomplish. The goal of pharmaco- 
therapy is to use the fewest medications and lowest 
dosages to control symptoms adequately, taking 
into consideration patient age, tolerance, and thera- 
peutic response. Patients must be monitored regu- 
larly for adverse effects, including clinical changes 
in the nasal mucosa. 
Palliative measures in the management of allergic 
rhinitis include air humidification and sodium chlo- 
ride nasal spray preparations. Initial pharmacother- 
apy generally includes oral antihistamines and de- 
congestants to control acute symptoms; these 
agents are especially useful in the presence of ocu- 
lar pruritus and lacrimination. Congestion and rhin- 
orrhea respond well to topical decongestants; how- 
ever, these preparations must be discontinued after 
3-5 days to prevent rebound congestion. Patients 
who have adverse effects or inadequate reponse to 
initial therapy, or who require extended treatment, 
should be considered for intranasal corticosteroid or 
cromolyn sodium therapy. Although beneficial as a 
prophylactic agent prior to the onset of a major aller- 
gen season, cromolyn sodium has not been as ef- 
fective as topical corticosteroids once the symp- 
toms of rhinitis develop. Since the currently 
available intranasal corticosteroids (BDP and fluni- 
solide) are comparable in therapeutic efficacy, prod- 
uct selection is based primarily on patient response 
and tolerance. The newer aqueuos, pump sprays 
seem to be most acceptable to patients. lntranasal 
ipratropium bromide can effectively decrease rhi- 
norrhea and nasal hypersecretion, and may soon be 
available in the United States. Other investigational 
agents, including the corticosteroids budesonide 
and flucortin, and the mast cell-stabilizing agent ne- 
docromil, show promising results in clinical trials. 
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